Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy

This article was originally published in The Gray Sheet

  • News

Executive Summary

Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.

You may also be interested in...



Research in Brief

Neuronetics releases long-term data on NeuroStar TMS therapy for depression. Bayesian methods confirm stenting matches surgery in patients with unprotected left-main disease. More research briefs.

Reimbursement In Brief

Latest news from the Medicare agency and other payers.

Regulatory News In Brief

User fees to go down next year

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT030482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By